AU2018205885A1 - Peptides for treating Sjogren's syndrome - Google Patents

Peptides for treating Sjogren's syndrome Download PDF

Info

Publication number
AU2018205885A1
AU2018205885A1 AU2018205885A AU2018205885A AU2018205885A1 AU 2018205885 A1 AU2018205885 A1 AU 2018205885A1 AU 2018205885 A AU2018205885 A AU 2018205885A AU 2018205885 A AU2018205885 A AU 2018205885A AU 2018205885 A1 AU2018205885 A1 AU 2018205885A1
Authority
AU
Australia
Prior art keywords
seq
peptide
expression
pharmaceutical composition
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018205885A
Other languages
English (en)
Inventor
Edna Mozes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of AU2018205885A1 publication Critical patent/AU2018205885A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2018205885A 2017-01-05 2018-01-04 Peptides for treating Sjogren's syndrome Abandoned AU2018205885A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762442441P 2017-01-05 2017-01-05
US62/442,441 2017-01-05
US201762481702P 2017-04-05 2017-04-05
US62/481,702 2017-04-05
US201762557153P 2017-09-12 2017-09-12
US62/557,153 2017-09-12
PCT/IL2018/050012 WO2018127914A1 (en) 2017-01-05 2018-01-04 Peptides for treating sjogren's syndrome

Publications (1)

Publication Number Publication Date
AU2018205885A1 true AU2018205885A1 (en) 2019-06-27

Family

ID=61157250

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018205885A Abandoned AU2018205885A1 (en) 2017-01-05 2018-01-04 Peptides for treating Sjogren's syndrome

Country Status (8)

Country Link
US (1) US11167005B2 (cg-RX-API-DMAC7.html)
EP (1) EP3565574A1 (cg-RX-API-DMAC7.html)
JP (1) JP7242059B2 (cg-RX-API-DMAC7.html)
CN (1) CN110139659B (cg-RX-API-DMAC7.html)
AU (1) AU2018205885A1 (cg-RX-API-DMAC7.html)
CA (1) CA3047706A1 (cg-RX-API-DMAC7.html)
IL (1) IL267426B2 (cg-RX-API-DMAC7.html)
WO (1) WO2018127914A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116287183B (zh) * 2022-11-18 2023-11-03 中国医学科学院北京协和医院 一组用于诊断干燥综合征的分子标志物组合

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613536B1 (en) 1995-03-28 2003-09-02 Yeda Research And Development Co. Ltd. Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
NZ541659A (en) 2003-01-14 2007-05-31 Teva Pharma Pharmaceutical composition comprising with a pH between 4 and 9 to treat SLE comprising an aqueous carrier, a pharmaceutically acceptable salt of a peptide and a substituted beta-cyclodextrin
DK1594434T3 (da) 2003-01-14 2017-01-02 Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science Parenterale formuleringer af peptide til behandling af systemisk lupus erythematosus
AU2005276117C1 (en) * 2004-08-23 2013-04-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Peptide inhibitors for mediating stress responses
KR20080074120A (ko) * 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
US20100322928A1 (en) 2007-01-19 2010-12-23 Yeda Research And Development Co., Ltd. Methods of diagnosing, monitoring treatment and treating systemic lupus erythematosus (sle)
WO2014052393A2 (en) 2012-09-25 2014-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for the diagnosis and treatment of sjögren's syndrome
US20180043016A1 (en) 2016-08-11 2018-02-15 Xtl Biopharmaceuticals Ltd. Pharmaceutical compositions comprising 0.25 mg dose of synthetic human peptides for treating systemic lupus erythematosus
US20180043017A1 (en) 2016-08-11 2018-02-15 Xtl Biopharmaceuticals Ltd. Pharmaceutical compositions comprising 0.5 mg dose of synthetic human peptides for treating systemic lupus erythematosus

Also Published As

Publication number Publication date
US20190351004A1 (en) 2019-11-21
WO2018127914A1 (en) 2018-07-12
CA3047706A1 (en) 2018-07-12
JP2020505324A (ja) 2020-02-20
EP3565574A1 (en) 2019-11-13
JP7242059B2 (ja) 2023-03-20
CN110139659B (zh) 2023-07-28
US11167005B2 (en) 2021-11-09
IL267426B1 (en) 2023-11-01
CN110139659A (zh) 2019-08-16
IL267426A (en) 2019-08-29
IL267426B2 (en) 2024-03-01

Similar Documents

Publication Publication Date Title
EP3065765B1 (en) Use of il-22 dimers in manufacture of medicaments for treating pancreatitis
TW201039843A (en) Compositions and methods for induced tolerance
FI3356386T3 (fi) Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä
AU2023233094B2 (en) Anti-inflammatory agents
WO2015138638A1 (en) Long acting trail receptor agonists for treatment of autoimmune diseases
EP1455766B1 (en) Thymosin alpha 1 peptide/polymer conjugates
JP2021514183A (ja) 改変免疫調節ペプチド
US11167005B2 (en) Peptides for treating Sjogren's syndrome
US12552848B2 (en) Hydrochloride salts of C5a receptor agonist peptides
JP2007500693A (ja) 移植片拒絶反応を予防するための合成ペプチドコポリマーを含む併用療法
ES2358018T3 (es) Uso de compuestos de kahalalida para la fabricación de un medicamento para el tratamiento de la psoriasis.
ES2292594T3 (es) E-selectina para tratar o prevenir accidentes cerebrovasculares.
HK40012327A (en) Peptides for treating sjogren's syndrome
WO2008037497A2 (en) Galectin-2 for the treatment of inflammatory diseases of the skin
WO2022189659A1 (en) Trem-1 inhibitors for the treatment of marfan syndrome
AU2016275295B2 (en) Multi-peptide composition
KR102647183B1 (ko) 유산균 유래 단백질과 항암 펩타이드를 포함하는 융합 단백질 및 이의 용도
US20200360484A1 (en) Ndp-msh for treatment of inflammatory and/or neurodegenerative disorders of the cns
KR20150035495A (ko) 화농성 비부비동염 치료를 위한 티모신 알파의 용도

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application